Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06282575
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
This study is currently enrolling.Associated Conditions: Liver CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis is an open-label, randomized, multicenter, phase 3 study to investigate the efficacy and safety of zanidatamab plus CisGem with or without a PD-1/L1 inhibitor (physician’s choice of either...
-
NCT05914116
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Celebration, FloridaThe main goal of this study is to test whether the study drug is safe and tolerable in patients with advanced/unresectable, or metastatic solid tumors (including small cell lung cancer, non-small cell...
-
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
This study is currently enrolling.Associated Conditions: LymphomaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe primary objective of the study is to demonstrate that epcoritamab
with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy
(CIT) in subjects with previously untreated FL. The primary... -
NCT04408625
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
This study is currently enrolling.Associated Conditions: AlzheimersResearch Area: Neuroscience ResearchResearch Location: Orlando, FloridaThe purpose of this open label study is to assess the safety, tolerability, and effects of LY3884963 on plasma (the liquid component of blood) and/or cerebrospinal fluid (CSF; fluid from the area...
-
NCT04127578
Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL)
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaParkinson’s disease is a slowly progressive and disabling disease of the central nervous system that causes problems with movement, such as shaking, stiffness, slow movement, and difficulty walking...
-
NCT05332054
Long-Term Follow-up Study (LTFS): An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
This study is currently enrolling.Research Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaCaribou's CAR-T cell product is a genetically modified cell therapy, meaning it is designed to change the expression of a gene or alter natural properties of living cells. Healthy donor T cells have...
-
NCT06072612
A Phase 3 Randomized, Open-label Study Comparing the Bria-IMT regimen in combination with Check Point Inhibitor vs Physician’s Choice in Metastatic Breast Cancer (BRIA-ABC)
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this research study is to assess the safety and effectiveness of an experimental therapy for advanced breast cancer called Bria-IMT (SV-BR-1-GM) in combination with the immune...
-
NCT06132893
A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of the BHV7000 in Subjects with Refractory Focal Onset Epilepsy
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaThis is a research study to test a new investigational drug. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). The main purpose of this study...
-
NCT06008093
A Phase IIIb, Randomized, Multicenter, Open-label study, to assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum Based Chemotherapy for First Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients who have Mutations or Co mutations in STK11, KEAP1, or KRAS (TRITON)
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaTo assess the efficacy of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in terms of OS, in participants with non-squamous histology who have metastatic...
-
NCT06189963
NKGen Biotech, Inc. “A Phase 1/2a Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants with Moderate Alzheimer’s Disease (Study SNK01-AD01)”
This study is currently enrolling.Research Area: Neuroscience ResearchResearch Location: Orlando, FloridaThe primary purpose of this research is to evaluate the safety of NK cell therapy when given alone. A secondary objective is to evaluate any preliminary efficacy by the change in cognitive assessment...
-
NCT06072781
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
This study is currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of...
-
NCT05154487
A Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
This study is currently enrolling.Associated Conditions: Endometrial CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find out if the combination of the drugs alpelisib and fulvestrant is better or worse than the usual approach for your type of cancer. The usual approach is defined as...